Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02440685
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:07.602761+00:00
Published At
2023-06-07T00:00:00+00:00
Record Updated At
2023-06-07
Results Posted At
2023-06-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Lymphoma, Follicular", "Cancer", "Neoplasm", "Tumor", "Lymphoma, Malignant", "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "B-Cell Chronic Lymphocytic Leukemia", "B-Cell Leukemia, Chronic", "B-Lymphocytic Leukemia, Chronic", "Chronic Lymphocytic Leukemia", "Leukemia, Lymphocytic, Chronic", "Leukemia, Lymphocytic, Chronic, B Cell", "Myelofibrosis", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "Lymphoma, T Cell, Peripheral", "Peripheral T-Cell Lymphoma", "T-Cell Lymphoma, Peripheral"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-06-07"
protocolSection.identificationModule.nctId
"NCT02440685"
protocolSection.identificationModule.officialTitle
"A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-06-07"

Study condition terms

  • Lymphoma, Large B-Cell, Diffuse (protocolSection.conditionsModule.conditions)
  • Lymphoma, Mantle-Cell (protocolSection.conditionsModule.conditions)
  • Lymphoma, Follicular (protocolSection.conditionsModule.conditions)
  • Cancer (protocolSection.conditionsModule.conditions)
  • Neoplasm (protocolSection.conditionsModule.conditions)
  • Tumor (protocolSection.conditionsModule.conditions)
  • Lymphoma, Malignant (protocolSection.conditionsModule.conditions)
  • Lymphoma, B-cell (protocolSection.conditionsModule.conditions)
  • Lymphoma, Non-Hodgkin (protocolSection.conditionsModule.conditions)
  • B-Cell Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • B-Cell Leukemia, Chronic (protocolSection.conditionsModule.conditions)
  • B-Lymphocytic Leukemia, Chronic (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Leukemia, Lymphocytic, Chronic (protocolSection.conditionsModule.conditions)
  • Leukemia, Lymphocytic, Chronic, B Cell (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Chronic Idiopathic Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Idiopathic Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Lymphoma, T Cell, Peripheral (protocolSection.conditionsModule.conditions)
  • Peripheral T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • T-Cell Lymphoma, Peripheral (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.